Stock Track | Anavex Life Sciences Soars 9.85% in Pre-Market on EMA Acceptance of Alzheimer's Drug Filing

Stock Track

2024-12-23

Anavex Life Sciences Corp. (AVXL) witnessed a significant surge of 9.85% in its stock price during the pre-market trading session on Monday. This rally was fueled by positive news regarding the company's Alzheimer's disease drug candidate, blarcamesine.

The European Medicines Agency (EMA) has accepted for review Anavex's Marketing Authorization Application (MAA) for blarcamesine, an investigational oral treatment for Alzheimer's disease. This development brings the company a step closer to potentially offering a novel treatment option for Alzheimer's patients in Europe.

Blarcamesine has demonstrated promising results in clinical trials, including the ability to slow cognitive decline in early-stage Alzheimer's patients while exhibiting a favorable safety profile. The drug aims to target the underlying pathology of Alzheimer's disease by enhancing autophagy, a cellular process that helps maintain homeostasis.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1137770145"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1137770145\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1137770145?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-23 20:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137770145","market":"us","top_or_hot":-1,"title":"Stock Track | Anavex Life Sciences Soars 9.85% in Pre-Market on EMA Acceptance of Alzheimer's Drug Filing","media":"Stock Track","content":"<p>Anavex Life Sciences Corp. (AVXL) witnessed a significant surge of 9.85% in its stock price during the pre-market trading session on Monday. This rally was fueled by positive news regarding the company's Alzheimer's disease drug candidate, blarcamesine.</p>\n\n<p>The European Medicines Agency (EMA) has accepted for review Anavex's Marketing Authorization Application (MAA) for blarcamesine, an investigational oral treatment for Alzheimer's disease. This development brings the company a step closer to potentially offering a novel treatment option for Alzheimer's patients in Europe.</p>\n\n<p>Blarcamesine has demonstrated promising results in clinical trials, including the ability to slow cognitive decline in early-stage Alzheimer's patients while exhibiting a favorable safety profile. The drug aims to target the underlying pathology of Alzheimer's disease by enhancing autophagy, a cellular process that helps maintain homeostasis.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Anavex Life Sciences Soars 9.85% in Pre-Market on EMA Acceptance of Alzheimer's Drug Filing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Anavex Life Sciences Soars 9.85% in Pre-Market on EMA Acceptance of Alzheimer's Drug Filing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-12-23 20:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Anavex Life Sciences Corp. (AVXL) witnessed a significant surge of 9.85% in its stock price during the pre-market trading session on Monday. This rally was fueled by positive news regarding the company's Alzheimer's disease drug candidate, blarcamesine.</p>\n\n<p>The European Medicines Agency (EMA) has accepted for review Anavex's Marketing Authorization Application (MAA) for blarcamesine, an investigational oral treatment for Alzheimer's disease. This development brings the company a step closer to potentially offering a novel treatment option for Alzheimer's patients in Europe.</p>\n\n<p>Blarcamesine has demonstrated promising results in clinical trials, including the ability to slow cognitive decline in early-stage Alzheimer's patients while exhibiting a favorable safety profile. The drug aims to target the underlying pathology of Alzheimer's disease by enhancing autophagy, a cellular process that helps maintain homeostasis.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AVXL","symbol_name":"Anavex Life Sciences Corp.","start_time":0,"source_url":"","article_id":"1137770145","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137770145","pubTimestamp":1734956668,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Anavex Life Sciences Corp.  witnessed a significant surge of 9.85% in its stock price during the pre-market trading session on Monday. This rally was fueled by positive news regarding the company's Alzheimer's disease drug candidate, blarcamesine.The European Medicines Agency  has accepted for review Anavex's Marketing Authorization Application  for blarcamesine, an investigational oral treatment for Alzheimer's disease. This development brings the company a step closer to potentially offering a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AVXL":"Anavex Life Sciences Corp."},"translate_title":"EMA接受阿尔茨海默氏症药物申请后，Anavex Life Sciences盘前股价飙升9.85%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVXL":1},"content_text":"Anavex Life Sciences Corp. (AVXL) witnessed a significant surge of 9.85% in its stock price during the pre-market trading session on Monday. This rally was fueled by positive news regarding the company's Alzheimer's disease drug candidate, blarcamesine.\nThe European Medicines Agency (EMA) has accepted for review Anavex's Marketing Authorization Application (MAA) for blarcamesine, an investigational oral treatment for Alzheimer's disease. This development brings the company a step closer to potentially offering a novel treatment option for Alzheimer's patients in Europe.\nBlarcamesine has demonstrated promising results in clinical trials, including the ability to slow cognitive decline in early-stage Alzheimer's patients while exhibiting a favorable safety profile. The drug aims to target the underlying pathology of Alzheimer's disease by enhancing autophagy, a cellular process that helps maintain homeostasis.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}